- Home
- RYTM
as 11-21-2024 4:00pm EST
Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 3.1B | IPO Year: | 2017 |
| Target Price: | $62.30 | AVG Volume (30 days): | 701.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.33 | EPS Growth: | N/A |
| 52 Week Low/High: | $31.53 - $68.58 | Next Earning Date: | 11-05-2024 |
| Revenue: | $112,530,000 | Revenue Growth: | 81.55% |
| Revenue Growth (this year): | 63.95% | Revenue Growth (next year): | 43.24% |
Stock Insider Trading Activity of Rhythm Pharmaceuticals Inc. (RYTM)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Lee Jennifer Kayden | RYTM | EVP, Head of North America | Nov 11 '24 | Sell | $67.15 | 66,861 | $4,434,882.42 | 972 | |
| Shulman Joseph | RYTM | Chief Technical Officer | Nov 11 '24 | Sell | $66.87 | 13,281 | $882,340.74 | 6,677 | |
| Cramer Pamela J. | RYTM | Chief Human Resources Officer | Nov 6 '24 | Sell | $62.50 | 9,375 | $585,940.00 | 13,500 | |
| GOOD JENNIFER L | RYTM | Director | Sep 17 '24 | Sell | $52.40 | 31,751 | $1,663,803.20 | 3,000 | |
| TETRAULT LYNN A. | RYTM | Director | Sep 9 '24 | Sell | $49.97 | 20,700 | $1,028,991.13 | 3,350 | |
| Cramer Pamela J. | RYTM | Chief Human Resources Officer | Sep 9 '24 | Sell | $50.03 | 4,099 | $205,062.31 | 13,500 | |
| GOOD JENNIFER L | RYTM | Director | Sep 9 '24 | Sell | $50.45 | 37,241 | $1,878,700.45 | 3,000 | |
| TETRAULT LYNN A. | RYTM | Director | Aug 26 '24 | Sell | $50.01 | 4,300 | $215,028.81 | 3,350 | |
| Cramer Pamela J. | RYTM | Chief Human Resources Officer | Aug 26 '24 | Sell | $50.01 | 3,200 | $160,017.92 | 13,500 | |
| GOOD JENNIFER L | RYTM | Director | Aug 26 '24 | Sell | $50.01 | 14,508 | $725,526.22 | 3,000 |
Latest Rhythm Pharmaceuticals Inc. News
RYTM Breaking Stock News: Dive into RYTM Ticker-Specific Updates for Smart Investing
Investor's Business Daily
3 days ago
Biotech Stock Attempts To End Losing Streak, Lands Back in Buy Zone
GlobeNewswire
3 days ago
Rhythm Pharmaceuticals Announces Five Presentations at ESPE 2024, including New Real-world Data in Pediatric Patients with Acquired or Congenital Hypothalamic Obesity Treated with Setmelanotide
GlobeNewswire
8 days ago
Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Study of Setmelanotide in Patients Between 2 and 5 Years Old in The Lancet Diabetes & Endocrinology
GlobeNewswire
8 days ago
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
Simply Wall St.
9 days ago
High Growth Tech Stocks Featuring Three Prominent US Companies
Simply Wall St.
14 days ago
Rhythm Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations
GuruFocus.com
15 days ago
Rhythm Pharmaceuticals Inc (RYTM) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...
GlobeNewswire
15 days ago
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences
Compare RYTM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RYTM Rhythm Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.